Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine

Stopped early · Phase 2

Conditions studied: Weight Gain

In brief

The purpose of this study is to evaluate the relative risks and benefits of two approaches to the control of weight gain and other negative side effects in children and adolescents on 2nd generation antipsychotics (SGA): * Healthy lifestyle instruction (nutritional and physical activity surveillance and advice) + continuation of current SGA; * Add the diabetes drug, metformin + continuation of current SGA.

Key facts

Study ID
NCT00617058
Run by
University of North Carolina, Chapel Hill
People needed
1
Starts
2007-03-01
Expected to finish
2010-09-01
Last updated by the study team
2012-12-31

Who can join

Age: 10 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.